Dr. Gilles Pages obtained his Ph.D. in Molecular Biology from Nice University France in 1990. He then joined his post-doc the group of Dr. Jacques Pouyssegur to clone the cDNA and genes for MAP Kinases. He obtained a permanent position as an Assistant Professor at the University of Nice Sophia Antipolis in 1991. For ten years he developed strong research in cell signaling and demonstrated the pivotal role of MAP Kinases in cell proliferation and tumor development. After several years dedicated to fundamental research, he decided to apply his knowledge to translational research. Therefore he studied the importance of the MAP Kinase/ERK pathway in the regulation of expression of Vascular Endothelial Factor (VEGF). He established a link between active mutations of the RAS/RAF/MEK/ERK pathway and tumor vascularization by showing the ERK up-regulated VEGF expression through the stimulation of the transcription of its gene and the stabilization of its mRNA. Since 2008, Gilles Pages has more specifically focused on renal cell carcinoma (RCC), a paradigm of exacerbated vascularization and the use of anti-angiogenic drugs. During the last few years, he deciphered several mechanisms of resistance to anti-angiogenic therapies including lysosome sequestration, a genetic adaptation of tumor cells, production of pro-angiogenic cytokines by tumor cells that are redundant of VEGF, and finally the development of a lymphatic network under the pressure of selection exerted by AAG